See BOXED WARNINGS, WARNINGS, and PRECAUTIONS.
Premarin Intravenous for injection is indicated for short-term use. However, the warnings, precautions and adverse reactions associated with oral Premarin treatment should be taken into account.
The following adverse reactions have been identified during post-approval use of oral or intravenous Premarin. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Abnormal uterine bleeding/spotting.
Dysmenorrhea or pelvic pain.
Increase in size of uterine leiomyomata.
Vaginitis, including vaginal candidiasis.
Change in amount of cervical secretion.
Change in cervical ectropion.
Tenderness, enlargement, pain, discharge, galactorrhea.
Fibrocystic breast changes.
Deep and superficial venous thrombosis.
Increase in blood pressure.
Abdominal cramps, bloating.
Increased incidence of gallbladder disease.
Enlargement of hepatic hemangiomas.
Chloasma or melasma that may persist when drug is discontinued.
Loss of scalp hair.
Retinal vascular thrombosis.
Intolerance to contact lenses.
Central Nervous System
Exacerbation of chorea.
Exacerbation of epilepsy.
Possible growth potentiation of benign meningioma.
Increase or decrease in weight.
Aggravation of porphyria.
Changes in libido.
Hypocalcemia (preexisting condition).
Injection site pain.
Injection site edema.
Phlebitis (injection site).
Exacerbation of asthma.